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S U M M A R Y
Background: The generation of antibodies (anti-HBe) against hepatitis B virus (HBV) e antigen (HBeAg)
often coincides with clinical remission in chronic HBV patients. We aimed to examine the effect of
maternal anti-HBe in protection against HBV mother-to-child transmission (MTCT).
Methods: A total of 140 chronic HBV-infected pregnant women participated in this study. Before
delivery, maternal HBV serological markers and HBV viral load were determined and anti-HBe titers
were semi-quantiﬁed. Neonatal hepatitis B surface antigen (HBsAg) and HBV-DNA status were
determined from cord blood. The children were followed to age 1–3 years.
Results: The HBV-DNA positive rate in cord blood was 75.61% (31/41) in those who were born to mothers
with serum HBV-DNA >106 IU/ml, which was signiﬁcantly higher than in those who were born to
mothers with HBV-DNA <106 IU/ml (3/99, 3.03%; p < 0.0001). However, 10 newborns from mothers
with serum HBV-DNA >106 IU/ml had no detectable HBV-DNA in cord blood; anti-HBe was positive with
a median titer of 10 (interquartile range 10–55). A total of 84 children who received hepatitis B immune
globulin (HBIG) within 12 h after birth and who completed three doses of recombinant HBV vaccination
were followed to age 1–3 years (up to May 2014). All 56 children who were born to mothers with serum
HBV-DNA levels <106 IU/ml were HBsAg-negative. Five of the 22 children born to anti-HBe-negative
mothers with serum HBV-DNA >106 IU/ml acquired an HBsAg-positive status. However, none of the six
children who were born to anti-HBe-positive/weak-positive mothers with serum HBV-DNA >106 IU/ml
acquired an HBsAg-positive status.
Conclusions: The presence of maternal anti-HBe is protective against HBV MTCT, independent of the
maternal serum HBV viral load.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Neonatal hepatitis B vaccination is an important strategy for
controlling hepatitis B virus (HBV) infection and has proven to be
successful worldwide.1–3 Mother-to-child transmission (MTCT) has
been found to be a primary reason for vaccination failure.3–7 MTCT
may occur prenatally, during delivery, or early post partum. It has been
reported that hepatitis B surface antigen (HBsAg) is detectable in* Corresponding authors.
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).amniotic ﬂuid, cord blood, breast milk, vaginal ﬂuid, and infant gastric
contents.8 Understanding the protective and risk factors related to
MTCT is important for improving the vaccination strategy against HBV
infection. A recent study involving 214 Chinese infants who were born
to HBsAg-positive mothers and who received HBV vaccines together
with the hepatitis B immunoglobulin (HBIG) within 24 h after birth,
claimed that the infants infected via intrauterine transmission failed to
be protected effectively by injections of HBIG and vaccines.5 As some
amino acid residues in the HBsAg ‘a’ epitope differ between the
different HBV genotypes,9 it is unknown whether vaccination failure,
because HBIG was introduced in conjunction with HBV vaccination, is
related to HBV genotype.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
µFigure 1. Study ﬂow chart.
L.-L. Lu et al. / International Journal of Infectious Diseases 28 (2014) 41–4442A persistent positive hepatitis B e antigen (HBeAg) or HBV-DNA
status indicates active viral replication.10 Some studies have
reported that the combination of HBeAg and HBV-DNA is a more
sensitive marker of MTCT than HBeAg alone,11 but another study
failed to prove the association.12 During the course of chronic HBV
infection, the generation of antibodies against HBeAg (anti-HBe)
often coincides with normalization of liver biochemical tests and
with clinical remission.10,13 Some studies have demonstrated that
mothers with serum anti-HBe positivity have a signiﬁcantly lower
risk of MTCT, which correlates with low levels of serum HBV-
DNA.3–5 However, it is unclear whether serum levels of anti-HBe in
pregnant women are correlated with a reduced MTCT risk.
2. Materials and methods
2.1. Study subjects
Qidong is an area of China with a high prevalence of HBV
infection. In 1976, a general survey of HBsAg prevalence in adults
aged 30–69 years in this region estimated it to be 19.1% in men and
16.2% in women based on the reverse passive hemagglutination
assay.14,15
Between October 2010 and June 2013, a total of 140 HBsAg-
positive pregnant women, aged 21–40 years, who gave birth at
Qidong People’s Hospital, agreed to participate in our study. All of
them were chronic HBsAg carriers (serum HBsAg-positive status
was conﬁrmed for 6–7 months) and had not been vaccinated
against HBV in childhood. The study protocol was reviewed and
approved by the Ethics Committee of the Qidong Liver Cancer
Institute. Informed written consent was obtained from all
participants. A peripheral blood sample (5 ml) was drawn from
each mother 1 day before delivery. Umbilical cord blood samples
were collected within 15 min after the newborn was delivered,
prior to inoculations with HBIG and HBV vaccines. Blood samples
were processed within 12 h of being taken and all of the sera were
stored at 20 8C.
All neonates were administered 100 IU HBIG within 12 h after
birth and completed a three-dose regimen of 10 mg recombinant
HBV vaccine at 0, 1, and 6 months of age. The last follow-up was
done in May 2014. A total of 84 children were followed to 1–3 years
of age (Figure 1).
2.2. HBV serological assay
Serum HBsAg and HBeAg were determined using reagents from
Roche Diagnostics and a Cobas e601 analyzer (Roche Diagnostic
GmbH, Mannheim, Germany).
2.3. Semi-quantiﬁcation of serum anti-HBe
Serum anti-HBe was determined based on the competition
principle by ELISA using reagents from Roche in a Cobas e601
analyzer (Roche Diagnostic GmbH). The detection limit was 0.2 PEI
U/ml. The analyzer automatically calculated the cutoff index based
on the measurement of Cal1 and Cal2. The results of the samples
were determined to be positive if the cutoff index was <1. In this
anti-HBe-positive sample we diluted it in normal saline containing
1% bovine serum albumin (BSA) and re-detected it until the cutoff
index reached >1, which is considered negative for anti-HBe. The
highest dilution factor giving a positive result was recorded as the
anti-HBe titer.
2.4. Quantiﬁcation of HBV viral load in blood
The HBV-DNA copy number was measured by TaqMan real-
time PCR, as described previously,16 using reagents from BioAssayScience (Beijing, China). HBV-DNA was extracted from 100 ml
serum. The sensitivity of this assay was 50 IU/ml of HBV-DNA.
2.5. Sequencing of the HBV S gene and HBV genotyping
HBV-DNA was extracted from 200 ml serum using a QIAamp
MiniElute Virus Kit (Qiagen). The strictest precautions were taken
to avoid possible contamination.17 The HBV preS-S region of each
isolate was ampliﬁed by primers selected from the highly
conserved region, as reported previously.18 The ampliﬁed genes
were then analyzed ﬁrst by polyacrylamide gel electrophoresis
(PAGE) and then sequenced using two methods: the PCR products
were directly sequenced; meanwhile, the products were cloned
into pMD18-T vector (TaKaRa Dalian, China) and three different
clones of each isolate were picked up and sequenced individually
at the North China Genomic Center (Beijing, China) using an
automated sequencer (ABI 3730 XL Genetic Analyzer; Applied
Biosystems, Foster City, CA, USA).
Molecular Evolutionary Genetics Analysis software version 4.0
(MEGA 4.0) was used for the analysis of amino acids from the
sequenced HBV-DNA. Genotypes from the isolates were deter-
mined by constructing a phylogenetic tree using MEGA 4.0, as
described previously.16 The sequences of known HBV genotypes
from GenBank (genotype C, GU434374; genotype B, FJ386684) and
the sequenced isolates were aligned in the phylogenetic tree and
determined according to genetic distances and the clustering of
DNA sequences, as reported previously.16,19
2.6. Statistics
All analyses were performed using SAS 9.3 (SAS Institute, Inc.,
Cary, NC, USA). p-Values less than 0.05 were considered statisti-
cally signiﬁcant. All statistical tests were two-sided. Chi-square
tests were conducted among groups to compare their differences.
Odds ratios (OR) and 95% conﬁdence intervals (CI) were calculated
based on logistic regression models. The Wilcoxon rank sum test
was used to compare the differences in anti-HBe titers among
groups.
Figure 2. Effects of serum anti-HBe titers on maternal HBV transmission. Serum
titers of anti-HBe in maternal blood (A) and cord blood (B) and HBV mother-to-child
transmission when maternal HBV viral load was >106 IU/ml. The titer with
0 indicates anti-HBe-negative.
Table 2
HBsAg status in 84 followed children at age 1–3 years born to mothers with
different serum HBV-DNA levels
Maternal blood HBsAg in followed children
HBV-DNA, IU/ml Serum anti-HBe Total No. Positive No. Rate
106 Negative 9 0 0%
106 Positive 47 0 0%
>106 Negative 22 5a 22.7%
>106 Positive/weak positive 6 0 0%
HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; anti-HBe, hepatitis B e
antibody; HBeAg, hepatitis B e antigen.
a Three of them were HBsAg(pos)/HBeAg(pos)/anti-HBe(neg); two of them were
HBsAg(pos)/HBeAg(neg)/anti-HBe(neg).
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3.1. The positivity rate of HBV-DNA in cord blood is signiﬁcantly
increased in newborns from mothers with serum HBV-DNA >106 IU/ml
Among the 140 HBsAg-positive pregnant women, 21 were
HBsAg(pos)/HBeAg(neg)/anti-HBe(neg), 74 were HBsAg(pos)/
HBeAg(neg)/anti-HBe(pos), 31 were HBsAg(pos)/HBeAg(pos)/an-
ti-HBe(neg), four were HBsAg(pos)/HBeAg(pos)/anti-HBe(pos),
and10 were HBsAg(pos)/HBeAg(pos)/anti-HBe() (weak positive
for anti-HBe). The HBsAg-positive rate in cord blood was the highest
in newborns of mothers with serology markers of HBsAg(pos)/
HBeAg(pos)/anti-HBe(neg) (Supplementary Material, Table S1).
HBV subviral particles, which have no HBV-DNA, have identical
HBsAg with virion particles and are over-produced in serum.20,21
We then analyzed the relationship of maternal serum HBV-DNA
levels and the positivity of HBV-DNA in matched cord blood. The
HBV-DNA-positive rate in cord blood was 3.03% (3/99) in
newborns of the mothers with serum HBV-DNA <106 IU/ml
(Table 1). A total of 41 mothers had serum HBV-DNA >106 IU/ml.
Thirty-one newborns of these mothers had HBV-DNA detectable in
their cord blood with a signiﬁcantly higher HBV-DNA positivity
(75.61%, 31/41; p < 0.001) compared to those who were born to
mothers with serum HBV-DNA <106 IU/ml. However, 10 of the
newborns of mothers with serum HBV-DNA >106 IU/ml had no
HBV-DNA detectable in the matched cord blood (Table 1).
3.2. The presence of maternal anti-HBe antibodies decreases the MTCT
risk
Since the HBsAg-positive rate was lower in the cord blood of
those born to the mothers with HBsAg(pos)/HBeAg(pos)/anti-
HBe(pos) or HBsAg(pos)/HBeAg(pos)/anti-HBe() (Supplementary
Material, Table S1), we then analyzed the maternal serum titers of
anti-HBe and the risk of HBV-DNA positivity in cord blood. Among the
31 cases with HBV-positive cord blood, only four samples showed
trace amounts of anti-HBe, with a median titer of 2 (interquartile
range 2–3.5); among the 10 cases with HBV-negative cord blood, all
samples were anti-HBe-positive, with a median titer of 10 (inter-
quartile range 10–55) (Figure 2). These results suggest that the
presence of maternal anti-HBe antibodies could reduce the risk of
transmission of HBV from mother to fetus, even in mothers with high
viral loads.
In order to conﬁrm this protective effect of maternal anti-HBe,
we followed the children who received HBIG within 12 h after birth
and who completed the HBV vaccination series to 1–3 years of age.
It was possible to follow a total of 84 children up to May 2014
(Table 2). All 56 of the followed children who were born to mothers
with serum HBV-DNA <106 IU/ml were HBsAg-negative. AmongTable 1
Maternal HBV-DNA serum levels and MTCT risk











<50 53 0 0 3 5.7
50–103 12 0 0 3 25
1.1  103–104 12 0 0 3 25
1.1  104–105 13 1 7.7 4 30.8
1.1  105–106 9 2 22.2 5 55.6
>106 41 31 75.6 34 82.9
Chi-square 84.8 61.9
p-Value <0.0001 <0.0001
HBV, hepatitis B virus; MTCT, mother-to-child transmission; HBsAg, hepatitis B
surface antigen.the 22 followed children who were born to mothers with serum
HBV-DNA >106 IU/ml and anti-HBe-negative, three were
HBsAg(pos)/HBeAg(pos)/anti-HBe(neg) and two were HBsAg(pos)/
HBeAg(neg)/anti-HBe(neg). However, among the six followed
children who were born to mothers with serum HBV-DNA >106
IU/ml but positive/weak positive for serum anti-HBe, none acquired
HBsAg (Table 2). The follow-up results in vaccinated children
conﬁrmed the effect of maternal anti-HBe in protection from HBV
MTCT.
3.3. Analysis of HBV genotypes and the ‘a’ epitope mutation
We analyzed the HBV genotypes in those with HBV-DNA
detectable in their cord blood (Table 1). Of the 34 isolates, 29
(85.3%) were genotype C and ﬁve (14.7%) were genotype B.
However, the ‘a’ epitope of the HBV S gene in all 34 isolates was
identical to the genotypes C and B isolated from patients with
chronic HBV infection in the local area (data not shown).
4. Discussion
In this study, we found that the MTCT risk increased when
maternal serum HBV-DNA levels were >106 IU/ml. In addition, we
found that the presence of maternal anti-HBe in higher titers
decreased the MTCT risk, independent of maternal serum HBV-
DNA levels. These results demonstrate the protective effect of
maternal anti-HBe in reducing the risk of HBV MTCT.
It has been found that HBV infectivity is very different in HBV
infective chimpanzee serum from the pre-acute phases (ramp-up
viremia prior to hepatitis C core antibodies (anti-HBc)) and late
acute phases (anti-HBc-positive), even when the serum contains
L.-L. Lu et al. / International Journal of Infectious Diseases 28 (2014) 41–4444similar amounts of HBV-DNA.22 The reduced MTCT risk in mothers
with anti-HBe may potentially be due to the following mecha-
nisms: (1) passively transferred anti-HBe antibodies bind with
newly formed HBeAg and decrease its immune suppressing effect;
(2) anti-HBe antibodies may be able to cross-react with HBV
epitopes expressed on infected hepatocytes and form an immune
complex to facilitate the elimination of the infected cells by the
innate immune cells through functions such as antibody-depen-
dent cell-mediated cytotoxicity; (3) antibodies generated in the
mother mask HBsAg to block their infectivity even in situations
where serum anti-HBs is undetectable. As no suitable cell culture
model is currently available, the mechanism of anti-HBe in
protection from MTCT cannot be fully elucidated.
Intrauterine infection is signiﬁcantly correlated with maternal
serum HBV-DNA levels.7 The administration of HBIG and HBV
vaccines to infants born to HBsAg-positive mothers is the most
effective method for avoiding HBV MTCT and subsequently the
prevention of chronic HBV infection.3 However, vaccination failure
has been shown to occur most frequently in subjects born to
mothers with higher HBV-DNA levels, even with immunoprophy-
laxis intervention.5 Recently, it was found that during late
pregnancy, the occurrence of MTCT in Chinese women treated
with nucleoside analogs such as lamivudine23 and telbivudine24
was signiﬁcantly reduced, which may be due to the signiﬁcantly
lower maternal serum HBV-DNA levels. Although no anti-HBe
seroconversion happened before delivery in these treated pregnant
women, the conversion was observed in some of them when they
were treated continuously after delivery.24
The ‘a’ determinant, a conformational cluster of epitopes
located within the HBsAg, is the major target for the neutralizing
antibody produced during natural infection or following vaccina-
tion,25 and some cases of vaccination failure have been found to be
related to ‘a’ epitope mutations.26,27 We found no ‘a’ epitope
mutation present among the HBV-DNA we isolated from cord
blood. The cases of vaccination failure with administration of HBIG
and hepatitis B vaccine to infants born to HBsAg-positive mothers
cannot be fully attributed to ‘a’ epitope mutations. Although HBV
genotype C was the main genotype in our isolated HBV-DNA, the
ratio of genotype C to genotype B among the isolates from cord
blood was similar to the ratio found for the whole country of
China.28
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